Insoluble powder formulation as an effective nasal drug delivery system

被引:52
作者
Ishikawa, F
Murano, M
Hiraishi, M
Yamaguchi, T
Tamai, I
Tsuji, A
机构
[1] Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan
[2] Dainippon Pharmaceut Co Ltd, Pharmaceut Res Labs, Suita, Osaka 5640053, Japan
关键词
nasal delivery; powder; formulation; phenol red; cyanocobalamin; FITC-Dextran;
D O I
10.1023/A:1019881706159
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the utility of insoluble powder formulation for nasal systemic drug delivery. Methods. To compare the efficacy of liquid and powder formulations, the nasal absorption of drugs was examined in rats using hydrophilic compounds with various molecular weights (MW) such as phenol red, cyanocobalamin, and fluorescein isothiocyanate (FITC)-Dextrans, and several kinds of powder. Intranasal residence time was also compared among the different formulations. Results. All the drugs examined were absorbed through the nasal mucosa to varying extent; their systemic bioavailability decreased with increasing MW. Insoluble calcium carbonate (CaCO3) powder formulation provided increased absorption of drugs over the wide range of MW from 354 to 77,000 Da. In the case of phenol red, intranasal administration as a CaCO3 powder formulation resulted in a plasma concentration profile similar to that of an intravenous bolus dose due to its very rapid and complete absorption from the nasal cavity. Furthermore, improved bioavailability of FITC-Dextran (MW 4,400; FD-4) was also achieved with other insoluble powders as well as CaCO3, but not with soluble powders such as lactose, d-sorbitol, and d-mannitol. Insoluble powder formulation prolonged the residence time of FD-4 within the nasal cavity. Conclusions. Insoluble powder formulations improve nasal bioavailability predominantly by retarding drug elimination from the absorption site and appear to be effective for nasal systemic drug delivery.
引用
收藏
页码:1097 / 1104
页数:8
相关论文
共 31 条
[21]   ANALYSIS OF STRUCTURAL REQUIREMENTS FOR THE ABSORPTION OF DRUGS AND MACROMOLECULES FROM THE NASAL CAVITY [J].
MCMARTIN, C ;
HUTCHINSON, LEF ;
HYDE, R ;
PETERS, GE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (07) :535-540
[22]   RESTRICTED DEXTRAN TRANSPORT IN THE SHEEP LUNG LYMPH PREPARATION [J].
MCNAMEE, JE .
JOURNAL OF APPLIED PHYSIOLOGY, 1982, 52 (03) :585-590
[23]   DIRECT DRUG TRANSPORT FROM THE RAT NASAL CAVITY TO THE CEREBROSPINAL-FLUID - THE RELATION TO THE MOLECULAR-WEIGHT OF DRUGS [J].
SAKANE, T ;
AKIZUKI, M ;
TAKI, Y ;
YAMASHITA, S ;
SEZAKI, H ;
NADAI, T .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (05) :379-381
[24]   DRUG-METABOLISM IN THE NASAL-MUCOSA [J].
SARKAR, MA .
PHARMACEUTICAL RESEARCH, 1992, 9 (01) :1-9
[25]   NASAL INSULIN DELIVERY WITH DIMETHYL-BETA-CYCLODEXTRIN AS AN ABSORPTION ENHANCER IN RABBITS - POWDER MORE EFFECTIVE THAN LIQUID FORMULATIONS [J].
SCHIPPER, NGM ;
ROMEIJN, SG ;
VERHOEF, JC ;
MERKUS, FWHM .
PHARMACEUTICAL RESEARCH, 1993, 10 (05) :682-686
[26]   Mucosal drug delivery using cellulose derivatives as a functional polymer [J].
Suzuki, Y ;
Makino, Y .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :101-107
[27]  
Tsuneji N., 1984, J. Control. Release, V1, P15, DOI [10.1016/0168-3659(84)90017-8, DOI 10.1016/0168-3659(84)90017-8]
[28]   The biopharmaceutical aspects of nasal mucoadhesive drug delivery [J].
Ugwoke, MI ;
Verbeke, N ;
Kinget, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (01) :3-21
[29]  
VANBREE JBMM, 1988, J PHARMACOL EXP THER, V247, P1233
[30]   EFFECT OF ABSORPTION PROMOTERS ON THE NASAL ABSORPTION OF DRUGS WITH VARIOUS MOLECULAR-WEIGHTS [J].
YAMAMOTO, A ;
MORITA, T ;
HASHIDA, M ;
SEZAKI, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 93 (1-3) :91-99